Click to Download
PRESS RELEASE
18 October 2024
Press Release
Media Contacts:
IB Communications
Reithera Announces Multiple Presentations at 2024 ESGCT Annual Congress Showing the Potential of the Production of Genetic Vaccines
Rome, October 18, 2024 - ReiThera, the Italian-based CDMO offering best-in-class process development and GMP manufacturing services for viral vectors today announces six oral presentations at the European Society of Gene & Cell Therapy 31st Annual Meeting (ESGCT), to be held October 22-25 in Rome.
During ESGCT Reithera’s team will be available to share details about:
ReiCell-AAV: HEK293-derived cell line for AAV manufacture in suspension
The GRAd platform: gorilla derived adenoviral vector platform for genetic vaccine
The MVA platform: from MVA vector construction to GMP in adhesion and suspension
The HSV vector: an established process in GMP grade-B area
One-stop-shop: GMP DS & DP production and release from 2L to 2000L STR Bioreactor
"As CEO of ReiThera, I believe that participating in the ESGCT conference is crucial for fostering collaboration and innovation in the field of gene and cell therapy, allowing us to share our cutting-edge research and advancements with the scientific community and contribute to shaping the future of healthcare." – Stefano Colloca, CEO of ReiThera.
Come and join us at booth B14/16 in La Nuvola, EUR!
Schedule a meeting in advance: businessdevelopment@reithera.com
Oral Presentations details:
Title: GRAd as vaccine platform for COVID-19, HIV, and global health
Speaker: Angelo Raggioli
Angelo will be presenting the latest update on how the GRAd platform can be customized to deliver clinical efficacy an antinfective vaccine and immuno-oncology. In particular, initial data on the GRAd-HIV vaccine will be shared. GRAd-HIV is a program run in collaboration with IAVI & the Ragon Institute and it is supported by the Bill and Melinda Foundation.
Presentation Date/Time: Wed. 23rd 8.30-10.30
Session title: SESSION 3c: Infectious Diseases / Vaccines
Session Room: Meeting Room 2 ∙ PARALLEL
———
Title: Optimization of the two-plasmid system for AAV production
Speaker: Michela Gentile
Michela will be presenting the results of a dual plasmid system to produced AAV by using Stirred Tank bioreactor. Data on the proprietary ReiCell-AAV cell line platform will be also presented.
Presentation Date/Time: Wed. 23rd 13:30-14:30
Session title: LUNCHTIME SYMPOSIUM: PlasmidFactory - A spotlight on plasmid and minicircle DNA starting materials for AAV vectors
Session Room: Meeting Room 1
———
Title: How to increase AVV productivity in ReiCell-AAV by combining Virica’s VSA Technology
Presentation date: Thurs 24th 11:00-11:30
ReiThera & Virica will be presenting the latest results on AAV productivity improvement obtained by combining Virica’s VSA elements and ReiThera’s proprietary ReiCell-AAV cell line.
———
Title: An innovative and scalable chromatographic purification approach for Modified Vaccinia Ankara (MVA) manufacturing process
Speaker: Andrea Valeria Canosa
Andrea Valeria will be presenting the latest results on MVA vector downstream which includes a scalable chromatographic step complying with sterility condition typical of non filtrable vector produced in a GMP class B area.
Presentation Date/Time: Wed. 23th 13:30 -15:00
Session title: POSTER SESSION II
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0452
———
Title: Development of a reverse phase chromatography assays for quantification of detergent residuals in vaccine purification process
Speaker: Andrea di Santo
Andrea will be presenting the latest data on HPLC reverse phase chromatography assays targeting the residuals titer like Domiphen Bromide and Polysorbate 20 & 80 during manufacturing and Drug Substance release.
Presentation Date/Time: Tues. 22nd 19:30-21:00
Session title: POSTER SESSION I
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0455
———
Title: From bench to dose: building a robust and scalable cGMP manufacturing process for non-replicative Herpes Simplex Virus 1 (nrHSV-1) vector as a powerful gene therapy platform
Speaker: Giuseppina Miselli
Giuseppina will be presenting the manufacturing platform developed for HSV GMP production: an effective approach to deliver in a reduced timeframe Drug Substance and Drug Product for clinical use. The process was performed in accordance with sterility compliance typical of a non filtrable vector produced in GMP Class B area.
Presentation Date/Time: Thurs. 24th 14:00-15:30
Session title: POSTER SESSION III
Session Room: Concourse Level 1 and Mezzanine Concourse
Final abstract number: P1043
———
Title: Upstream process intensification for a gorilla derived adenoviral (GRAd) vector by using a perfusion system
Speaker: Alessia Noto
Alessia will be presenting data related the manufacturing process platform of a GRAd based vector by using cell density intensification by perfusion leading to the improvement of volumetric productivity
Presentation Date/Time: Thurs. 22nd 19:30-21:00
Session title: POSTER SESSION I
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0453
———
Title: Enhanced thermostability of a gorilla-derived adenoviral (grad) vector via e4 region chimerism
Speaker: Michela Gentile
Michela will be presenting additional data on the GRAd platform robustness and the enhanced stability improvement at +4°C and +37°C: a critical advantage in the global vaccine distribution.
Presentation Date/Time: Wed. 23th 13:30 -15:00
Session title: POSTER SESSION II
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0454
———
Title: A simplified AAV infectivity assay enhances efficiency and throughput
Speaker: Angelo Raggioli
Angelo will be presenting a shorter TCID50 methodology; a faster approach to investigate vector quality during process development.
Presentation Date/Time: Wed. 23th 13:30 -15:00
Session title: POSTER SESSION II
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0018
About ReiThera Srl
ReiThera Srl is a CDMO company dedicated to technology and process development and GMP manufacturing, providing support for the clinical translation of genetic vaccines and medicinal products for advanced therapies. The company has extensive expertise in developing scalable processes for viral-vector manufacturing and a consolidated experience in GMP production of Adeno-Associated Vector (AAV), Lentivirus, Adeno Viral vector (AdV), Modified Vaccinia Ankara and Herpes Simplex Vector.ReiThera's core manufacturing capacity is based in a state-of-the-art facility, which includes stirred-tank bioreactors at scales of 50L, 200L, 1000L, and 2000L, as well as fixed-bed bioreactors for cell growth in adherence. The GMP facility also comprises a filling suite and quality control laboratories.ReiThera's headquarters, R&D laboratories, and GMP facilities are located in Rome, Italy. For more information, visit www.reithera.com